

# CHRONIC ILLNESSES I PANEL

---

## EDITORIAL BOARD LIAISON

Michelle M. Richardson, Pharm.D., FCCP, BCPS  
*Special and Scientific Staff*  
William B. Schwartz Division of Nephrology  
Tufts Medical Center  
*Assistant Professor of Medicine*  
Tufts University School of Medicine  
Boston, Massachusetts

## CHRONIC HEART FAILURE

### Authors

Jo Ellen Rodgers, Pharm.D., FCCP, BCPS  
*Clinical Associate Professor*  
Division of Pharmacotherapy and Experimental  
Therapeutics  
Eshelman School of Pharmacy  
University of North Carolina at Chapel Hill  
Chapel Hill, North Carolina

Kristen Bova Campbell, Pharm.D., BCPS  
*Clinical Pharmacist*  
Department of Pharmacy  
Duke University Hospital  
Durham, North Carolina  
*Clinical Assistant Professor*  
Division of Pharmacy Practice and Experiential  
Education  
Eshelman School of Pharmacy  
University of North Carolina at Chapel Hill  
Chapel Hill, North Carolina

### Reviewers

Steven P. Dunn, Pharm.D., BCPS  
*Pharmacy Clinical Coordinator, Cardiology*  
Department of Pharmacy Services  
University of Virginia Health System  
Charlottesville, Virginia

Emilie L. Karpiuk, Pharm.D., BCPS, BCOP  
*Oncology Pharmacist*  
Department of Pharmacy  
Froedtert Hospital  
Milwaukee, Wisconsin

## ANTICOAGULATION IN CHILDREN

### Authors

Kathryn Timberlake, Pharm.D.  
*Clinical Pharmacy Specialist*  
Department of Pharmacy  
The Hospital for Sick Children  
Toronto, Ontario, Canada

Leonardo R. Brandao, M.D., MSc  
*Assistant Professor of Paediatrics*  
University of Toronto  
*Haemostasis and Thrombosis Service*  
Division of Paediatric Haematology/Oncology  
Department of Paediatrics  
The Hospital for Sick Children  
Toronto, Ontario, Canada

### Reviewers

Katherine Hammond Chessman, Pharm.D., FCCP,  
BCPS, BCNSP *Professor*  
Department of Clinical Pharmacy and  
Outcome Sciences  
*Pediatric Pharmacy Practice Residency Program Director*  
South Carolina College of Pharmacy  
Medical University of South Carolina Campus  
*Clinical Pharmacy Specialist*  
Pediatrics/Pediatric Surgery  
MUSC Children's Hospital  
Charleston, South Carolina

Kirsten H. Ohler, Pharm.D., BCPS  
*Neonatal/Pediatric Clinical Pharmacist*  
*Assistant Clinical Professor*  
Department of Pharmacy Practice  
University of Illinois at Chicago  
Chicago, Illinois

## WARFARIN PHARMACOGENETICS

### Authors

Jaekyu Shin, Pharm.D., M.S., BCPS  
*Assistant Professor of Clinical Pharmacy*  
Department of Clinical Pharmacy  
University of California San Francisco  
San Francisco, California

Larisa H. Cavallari, Pharm.D., FCCP, BCPS  
*Associate Professor*  
Department of Pharmacy Practice  
University of Illinois at Chicago  
Chicago, Illinois

### **Reviewers**

Gloria R. Grice, Pharm.D., BCPS  
*Associate Professor of Pharmacy Practice*  
Department of Pharmacy Practice  
St. Louis College of Pharmacy  
St. Louis, Missouri

Michelle M. Richardson, Pharm.D., FCCP, BCPS  
*Special and Scientific Staff*  
William B. Schwartz Division of Nephrology  
Tufts Medical Center  
*Assistant Professor of Medicine*  
Tufts University School of Medicine  
Boston, Massachusetts

*The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Book 5, Chronic Illnesses I chapters:*

H. Gwen Bartlett, Pharm.D., BCPS  
*Clinical Pharmacist III*  
Department of Pharmacy  
St. Francis Health Center  
Topeka, Kansas

Nicola G. Dahl, Pharm.D.  
*Medical Writer*  
Kanab, Utah

Julia Elenbaas, Pharm.D.  
Belton, Missouri

# DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

*Consultancies:* Marisa Battistella (Shire Pharmaceuticals); Elizabeth A. Boucher (Pediatric Pharmacy Advocacy Group); Kimberli M. Burgner (Hospital Corporation of America, Clinical Pharmacy Advisory Board); Steven Dunn (Cardea Rx/Johnson & Johnson); Michael E. Ernst (Takeda Pharmaceuticals); Shannon W. Finks (Novartis Pharmaceuticals); Christa M. George (Bayer, Ortho McNeil); Gloria Grice (Johnson & Johnson); Henry Halapy (Merck Frosst Canada, Ltd); Brian A. Hemstreet (Conexus Health); Lisa C. Hutchison (Arkansas Medicaid, Arkansas Foundation for Medical Care); Melanie S. Joy (National Institutes of Health, Fleet Laboratories, FDA); Elaine H. Morrato (U.S. Food and Drug Administration); Kirsten Ohler (ACCP [three presentations]); Patricia H. Powell (South Carolina Pharmacy Association); Valerie Prince (American Pharmacists Association, Alabama Board of Pharmacy); Jane M. Pruemmer (Hematology Oncology Pharmacy Association); Michelle Richardson (Amgen, QualityMetric); Marisel Segarra-Newnham (Tibotec Therapeutics, USP, Annals of Pharmacotherapy); Jeffrey T. Sherer (Sturge-Weber Foundation); Jaekyu Shin (University of California–San Diego)

*Stock Ownership:* Katherine H. Chessman (Procter & Gamble [spouse or significant other]); Lisa C. Hutchison (Cardinal Health); Melanie S. Joy (Katharos, Inc.); Emilie Karpiuk (Cardinal Health); Elaine H. Morrato – (Procter & Gamble [self]), Oncology Biotech Co. [spouse or significant other])

*Royalties:* Larisa H. Cavallari (Lexicomp, Inc.) Lisa C. Hutchison (ASHP); Melanie S. Joy (University of North Carolina); Jane M. Pruemmer (ASHP); Lynne M. Sylvia (Jones and Bartlett Publishing)

*Grants:* Larisa H. Cavallari (NIH, American Heart Association); Lisa B. Cohen (ASHP); Honoraria (Massachusetts Association of Health System Pharmacists; Connecticut Pharmacist Association); Gloria Grice (National Institutes of Health); Henry Halapy (Novo Nordisk Canada, Inc.); Brian A. Hemstreet (AstraZeneca); Anne L. Hume (AHRQ [two grants], HRSA); Lisa C. Hutchison (Boehringer Ingelheim, National Institutes of Health); Melanie S. Joy (National Institutes of Health, ACCP, Roche, University of North Carolina); Elaine H. Morrato (The Children’s Hospital Research Institute, Pfizer, Eli Lilly); Michelle Richardson (NIH NIDDK [two grants]); Jaekyu Shin (University of California – San Francisco); Meghan K. Sullivan (American Foundation for Pharmaceutical Education/ National Association of Chain Drug Stores Foundation); Patricia R. Wigle (Novartis, University of Cincinnati Health-UC [two grants])

*Honoraria:* Marisa Battistella (Shire Pharmaceuticals, Amgen); Jodie L. Elder (Michigan Pharmacists Association); Henry Halapy (Sanofi Aventis Canada, Inc.); Lisa C. Hutchison (ACCP, ASHP); Matt Kauflin (Cubist Pharmaceuticals, AstraZeneca); Patricia H. Powell (South Carolina Pharmacy Association); Jane M. Pruemmer (Curatio CME Institute, HOPA, Amgen); Michelle Richardson (Amgen); Tricia M. Russell (AstraZeneca, APhA); Jaekyu Shin (ACCP)

*Other:*

*Nothing to Disclose:* Teresa M. Bailey, Christopher Bernheisel, Leonardo R. Brandao, Kristen Bova Campbell, Clarence Chant, Bradley E. Hein, Brandi C. LaFrance, Marianne McCollum, Michael Remkus, Jo Ellen Rodgers, Beth A. Sproule, Kathryn Timberlake, Sarah Tomasello, Kimberly Metka Welch

**ROLE OF ACCP:** ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmacy Specialties (BPS). As part of its mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, has knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

**ROLE OF BPS:** The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at [www.bpsweb.org/recertification/general.cfm](http://www.bpsweb.org/recertification/general.cfm).

Other questions regarding recertification should be directed to:

Board of Pharmacy Specialties  
2215 Constitution Avenue NW  
Washington, DC 20037  
(202) 429-7591  
[www.bpsweb.org](http://www.bpsweb.org)